Combined Radiotherapy and Indomethacin for the Prevention of Heterotopic Ossification after Total Hip Arthroplasty

dc.contributor.authorPakos, E. E.en
dc.contributor.authorStafilas, K. S.en
dc.contributor.authorTsekeris, P. G.en
dc.contributor.authorPolitis, A. N.en
dc.contributor.authorMitsionis, G.en
dc.contributor.authorXenakis, T. A.en
dc.date.accessioned2015-11-24T18:31:39Z
dc.date.available2015-11-24T18:31:39Z
dc.identifier.issn0179-7158-
dc.identifier.urihttps://olympias.lib.uoi.gr/jspui/handle/123456789/16498
dc.rightsDefault Licence-
dc.subjectheterotopic ossificationen
dc.subjecttotal hip arthroplastyen
dc.subjectradiotherapyen
dc.subjectindomethacinen
dc.subjectcongenital hip diseaseen
dc.subjectpostoperative radiation-therapyen
dc.subjectnonsteroidal antiinflammatory drugsen
dc.subjectrandomized-trialen
dc.subjectectopic ossificationen
dc.subjectpredisposing factorsen
dc.subjectrisk-factorsen
dc.subjectfollow-upen
dc.subjectprophylaxisen
dc.subjectreplacementen
dc.subjectboneen
dc.titleCombined Radiotherapy and Indomethacin for the Prevention of Heterotopic Ossification after Total Hip Arthroplastyen
heal.abstractBackground and Purpose: Heterotopic ossification (HO) is a frequent complication following total hip arthroptasty. The aim of this study was to evaluate the efficacy of combined radiotherapy and indomethacin as compared to indomethacin atone for the prevention of HO after hip arthroplasty. Patients and Methods: 96 patients were prospectively enrolled to receive either a single dose of postoperative radiotherapy of 7.0 Gy and indomethacin for the first 15 postoperative days or indomethacin atone for the same period. A historical group of 50 patients that received indomethacin atone served as control. Primary endpoint was the radiographic evidence of HO at 6 months. Secondary endpoints were the evaluation of factors related to HO development, side effects from each treatment, and group differences in the clinical assessment with the Merle d'Aubigne Score. Results: Four patients in the combined-therapy group developed HO compared to 13 patients in the indomethacin group (p < 0.05) and 13 patients in the historical group (p < 0.05). One patient each in the combined group and the historical group developed Brooker III HO (nonsignificant difference). Duration of surgery and congenital hip disease were associated with HO development in the indomethacin groups, while age and congenital hip disease showed such an association in the combined-therapy group. The side effects and mean Merle d'Aubigne Score did not differ significantly between the three groups. Conclusion: Combined radiotherapy and indomethacin was more efficacious in preventing HO after total hip arthroplasty compared to indomethacin atone and should be considered for future investigation.en
heal.accesscampus-
heal.fullTextAvailabilityTRUE-
heal.identifier.secondary<Go to ISI>://000268639800004-
heal.identifier.secondaryhttp://link.springer.com/content/pdf/10.1007%2Fs00066-009-1954-3.pdf-
heal.journalNameStrahlentherapie Und Onkologieen
heal.journalTypepeer reviewed-
heal.languageen-
heal.publicationDate2009-
heal.recordProviderΠανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών και Τεχνολογιών. Τμήμα Βιολογικών Εφαρμογών και Τεχνολογιώνel
heal.typejournalArticle-
heal.type.elΆρθρο Περιοδικούel
heal.type.enJournal articleen

Αρχεία

Φάκελος/Πακέτο αδειών

Προβολή: 1 - 1 of 1
Φόρτωση...
Μικρογραφία εικόνας
Ονομα:
license.txt
Μέγεθος:
1.74 KB
Μορφότυπο:
Item-specific license agreed upon to submission
Περιγραφή: